Peerbridge Health Announces Funding Round Close

Despite heart disease being the leading cause of death in the United States, millions of people lack access to affordable, accurate diagnostics. Peerbridge Health is working to close that gap and has announced a series of milestones that will move it closer to that goal.

The company has closed its latest fundraising round and submitted its next-generation wearable—the Cor MDx—for U.S. Food and Drug Administration 510(k) clearance.

“We believe that life-saving cardiac diagnostics should not be a luxury, yet access to affordable diagnostics is still out of reach for so many people,” Peerbridge Health CEO Chris Darland said. “Too many families delay or avoid cardiac testing because it’s either too expensive or not offered in their community. Whether you live in a rural town, a big city, or anywhere in between, our mission is to provide you with access to the same quality of care.”

The latest funding round raised $7 million and will support Peerbridge’s commercial rollout of its latest generation product. The Cor MDx device represents a significant step forward in high-fidelity, real-time cardiac monitoring and is expected to launch relatively soon pending regulatory clearance.

The company also appointed Dan Reuvers to its Board of Directors. Reuvers has more than 30 years of leadership experience in the medtech industry, having served as CEO of Tactile Medical, as well as president of the neuro division of Integra LifeSciences. He also serves on the Board of Directors of Etac. His proven ability to scale health technology companies will make him an integral part of the team moving forward.

“Dan brings exactly the kind of experience we need right now as we move into this next phase,” Darland stated. “His experience enriches our leadership team, and we’re thrilled to officially welcome him to our board.”

Additionally, Peerbridge Health has expanded its sales team across three regions and plans to expand the launch beyond these initial areas. This expansion will focus on bringing hospital-grade cardiac diagnostics into primary care and cardiology clinics with the goal of catching disease as early as possible, thus reducing emergency room visits and improving patient outcomes. 

With these milestones, Peerbridge is advancing its mission to make high-quality, life-saving cardiac diagnostics accessible to everyone. By combining cutting-edge technology with a focus on affordability, the company is working to close gaps in healthcare and ensure that early detection is available to all patients.

Peerbridge Health is redefining cardiac diagnostics with low-cost, high-fidelity, non-invasive technology that detects critical heart conditions in just minutes. By combining quantum resonance signal processing with explainable artificial intelligence (AI), Peerbridge delivers hospital-grade insights at a fraction of the cost. The company is headquartered in Nashville, Tenn., and aims to make advanced diagnostics accessible to everyone, including those in underserved and rural communities.